


COPY

Applicant: Drewe, et al.

Application No.: 09/836,548

Filed: April 18, 2001

For: **Substituted 1,4-Thiazepine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof**



Due Date: None

Art-Unit: 1624

Examiner: Coleman, B.

Docket: 1735.0450001

Atty: RWE/RAS

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. PTO Fee Transmittal Form (PTO/SB/17);
3. Request to Correct Inventorship In A Non-Provisional Patent Application Under 37 C.F.R. § 1.48(a)(1);
4. Original Statement Under 37 C.F.R. § 1.48(a)(2) of A Person To Be Added or Deleted As An Inventor;
5. Original Substitute Declaration executed by all of the inventors;
6. Original Consent of the Assignee Under 37 C.F.R. § 1.48(a)(5) executed by Axys Pharmaceuticals, Inc. and Cytovia;
7. Our check no. 37216 in the amount of \$130.00 to cover the processing fee as set forth under 37 C.F.R. § 1.17(i); and
8. One (1) return postcard.

**Please Date Stamp And Return To Our Courier**

::ODMA\MHODMA\SKGF\_DC1;71147;1

COPY

Applicant: Drewe, et al.



Due Date: None

Art Unit: 1624

Application No.: 09/836,548

Filed: April 18, 2001

Examiner: Coleman, B.

Docket: 1735.0450001

Atty: RWE/RAS

For: Substituted 1,4-Thiazepine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Information Disclosure Statement;
3. Nineteen (19) pages of Form PTO-1449 citing sixty (60) references;
4. A copy of the sixty (60) cited references; and
5. One (1) return postcard.

Please Date Stamp And Return To Our Courier

::ODMA\MHODMA\SKGF\_DC1;71487;1